T1	Condition 6 22	hypersensitivity
T2	Drug 26 38	tetracycline
T3	Drug 40 51	doxycycline
T4	Drug 55 67	azithromycin
*	OR T3 T4 T2
T5	Scope 26 67	tetracycline, doxycycline or azithromycin
R1	Has_scope Arg1:T1 Arg2:T5	
T6	Drug 87 98	doxycycline
T7	Drug 100 112	azithromycin
T8	Drug 114 129	chloramphenicol
T9	Drug 131 141	rifampicin
T10	Drug 146 158	tetracycline
T11	Temporal 159 186	during the preceding 7 days
*	OR T10 T9 T8 T7 T6
T12	Scope 87 158	doxycycline, azithromycin, chloramphenicol, rifampicin, or tetracycline
R2	Has_temporal Arg1:T12 Arg2:T11	
T13	Condition 188 197	Pregnancy
T14	Observation 201 215	breast-feeding
*	OR T13 T14
T15	Condition 231 248	myasthenia gravis
T16	Condition 252 280	systemic lupus erythematosus
*	OR T15 T16
T17	Condition 311 320	infection
T18	Procedure 322 337	diagnostic test
R3	AND Arg1:T17 Arg2:T18	
T19	Condition 353 366	acute malaria
T20	Condition 368 374	dengue
T21	Condition 376 389	leptospirosis
T22	Condition 391 398	typhoid
T23	Condition 400 421	Japanese encephalitis
*	OR T23 T22 T21 T20 T19
T24	Scope 353 421	acute malaria, dengue, leptospirosis, typhoid, Japanese encephalitis
R4	Subsumes Arg1:T17 Arg2:T24	
T25	Condition 436 438	TB
T26	Procedure 442 454	TB treatment
T27	Temporal 455 468	in = 6 months
*	OR T25 T26
R5	Has_temporal Arg1:T26 Arg2:T27	
T28	Procedure 529 534	HAART
T29	Condition 543 546	HIV
R6	AND Arg1:T28 Arg2:T29	
T30	Multiplier 548 561	long term use
T31	Drug 565 583	immunosuppressants
R7	Has_multiplier Arg1:T31 Arg2:T30	
T32	Drug 590 598	steroids
T33	Drug 600 612	chemotherapy
T34	Drug 614 628	TNF-inhibitors
*	OR T34 T33 T32
T35	Scope 590 628	steroids, chemotherapy, TNF-inhibitors
R8	Subsumes Arg1:T31 Arg2:T35	
*	OR T28 T31
T36	Non-representable 650 900	Patients with severe disease whom the clinical team feel their condition necessitates the need for additional scrub typhus treatment beyond the allocated antibiotic treatment assigned at randomization (e.g. IV chloramphenicol and/or PO/NG rifampicin)
